Skip to content
Storytelling Co – Lifestyle
Author:
Immuneering Corporation
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
November 9, 2026
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
November 4, 2026
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
October 29, 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
October 26, 2026
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 2, 2026
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
September 28, 2026
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 10, 2026
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026
1
2
Next Page
→